Table 3.
Therapeutic and outcome data of the NPCM cases from this study.
| NPCM | Drug | Time of Treatment (Months) |
Time of Follow-Up (Months) |
Outcome | Sequel |
|---|---|---|---|---|---|
| Case 1 | AMB » SMZ-TMP + FCZ | 12 | - | Death | - |
| Case 2 | AMB » SMZ-TMP + FCZ | 27 | 96 | Cure | None |
| Case 3 | SMZ-TMP | 30 | 31 | Cure | None |
| Case 4 | SMZ-TMP + FCZ | 60 | 48 | Cure | None |
| Case 5 | SMZ-TMP + FCZ » FCZ 1 | 96 | UT | UT | UT |
| Case 6 | AMB » SMZ-TMP + FCZ | 48 | 24 | Cure | Tetraparesis 2 |
| Case 7 | SMZ-TMP + FCZ | 35 | UT | UT | UT |
| Case 8 | SMZ-TMP + FCZ | 14 | UT | UT | UT |
Legend: AMB (amphotericin B), SMZ-TMP (sulfamethoxazole/trimethoprim), FCZ (fluconazole), UT (under treatment). 1 Toxicity due to SMZ-TMP. 2 Need of walking support.